KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company yesterday filed an S-1/A, a post-effective amendment to the SB-2 it filed in early 2008. That filing in 2008 was for the purpose of registering common stock underlying warrants previously issued. The purpose of the amendment is to update the previously filed information with the Company’s recent filings. Subsequent to the time the Company filed the SB-2, the SEC eliminated the SB-2 form. The SEC allows companies to update the old SB-2 forms by filing a post-effective amendment on a form entitled S-1/A. Yesterday’s filing replaces the S-1/A the Company filed on May 1, 2009, as there was an electronic formatting error. The content of the two filings are the same.
